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Abstract
Background: The benefit of cytoreductive nephrectomy (CN) for overall survival (OS) is
unclear in patients with synchronous metastatic renal cell carcinoma (mRCC) in the era
of targeted therapy.
Objective: To determineOS benefit of CN comparedwith no CN inmRCC patients treated
with targeted therapies.
Design, setting, and participants: Retrospective data from patients with synchronous
mRCC (n = 1658) from the International Metastatic Renal Cell Carcinoma Database
Consortium (IMDC) were used to compare 982 mRCC patients who had a CN with
676 mRCC patients who did not.
Outcome measurements and statistical analysis: OS was compared and hazard ratios
(HRs) adjusted for IMDC poor prognostic criteria.
Results and limitations: Patients who had CN had better IMDC prognostic profiles versus
those without (favorable, intermediate, or poor in 9%, 63%, and 28% vs 1%, 45%, and 54%,
respectively). The median OS of patients with CN versus without CN was 20.6 versus
Wh
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Conclusions: CNisbeneficial in synchronousmRCCpatients treatedwith targeted therapy,
even after adjusting for prognostic factors. Patients with estimated survival times<12mo
or fourormore IMDCprognostic factorsmaynotbenefit fromCN. This informationmayaid
in patient selection as we await results from randomized controlled trials.
Patient summary: We looked at the survival outcomes of metastatic renal cell carcinoma
patientswhodid or didnot have the primary tumor removed.We found thatmost patients
benefited from tumor removal, except for those with four or more IMDC risk factors.
# 2014 Published by Elsevier B.V. on behalf of European Association of Urology.
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Over the past decade, our molecular understanding of
metastatic renal cell carcinoma (mRCC) has vastly improved.
Since 2005, targeted therapies have been designed to target
pathways involved in RCC pathogenesis, leading to the
approval of the vascular endothelial growth factor (VEGF)
inhibitors sunitinib, sorafenib, pazopanib, bevacizumab, and
axitinib, and the mammalian target of rapamycin (mTOR)
inhibitors temsirolimus and everolimus. Targeted therapies
have demonstrated impressive gains in overall survival (OS),
progression-free survival (PFS), and response rates over the
previously utilized immunotherapies [1–3].
In the era of immunotherapy (1992–2004), a combined
analysis of two prospective randomized clinical trials from
the European Organization for Research and Treatment of
Cancer (EORTC) and SWOG demonstrated that cytoreduc-
tive nephrectomy (CN) followed by interferon-a treatment
had a 5.8-mo increased OS versus immunotherapy alone
(13.6 vs 7.8mo) [4–6]. The results solidified the role of CN in
the immunotherapy era of mRCC treatment. However, with
more effective targeted therapies largely supplanting
immunotherapy, it is not well understood if CN should
remain a part of the standard treatment protocol. The rates
of CN have declined since the introduction of targeted
therapy [7,8]. This large retrospective international study
was performed to address the survival benefit of CN in
mRCC patients treated with targeted therapy.
2. Methods
2.1. Patient population
Patient data were collected from 20 international cancer centers from
Canada, the United States, Belgium, South Korea, Japan, Denmark,
Greece, and Singapore. Patient inclusion criteria were composed ofmRCC
diagnosisofanytypeandtreatmentwithaVEGFormTORtargetedtherapy
(sunitinib, sorafenib, axitinib, bevacizumab, temsirolimus, pazopanib, or
everolimus).
Data were collected using uniform database software and templates.
Demographic, clinical, and laboratory data include those found to have
prognostic value [9–11] (Table 1). Laboratory values were standardized
against their respective institution upper limit of normal (ULN) and
lower limit of normal (LLN) values as necessary. Measured outcomes
included OS and PFS. This study received institutional review board
approval from each participating center.
2.2. Statistical analysis
The primary outcome was OS from the initiation of first-line targeted
therapy to the date of death or censored at last follow-up. PFS wasdefined as the initiation of targeted therapy to the date of progression,
drug cessation, or censored at last follow-up. Median OS and PFS
distributions were estimated using the Kaplan-Meier method.
Cox proportional hazards regression was used to determine hazard
ratios (HRs) for OS after adjustment for known International Metastatic
Renal Cell Carcinoma Database Consortium (IMDC) prognostic factors:
hemoglobin below LLN, corrected calcium greater than ULN, neutrophils
above ULN, platelets greater than ULN, Karnofsky performance status
<80%, and time from diagnosis to treatment <1 yr [11]. Adjusted HRs
and p values were reported. Subgroup analysis andHRswere determined
for IMDC favorable-, intermediate-, and poor-risk groups as well as other
covariates of interest.
Incremental survival benefits were compared between those who
received a CN versus those who did not in patients who survived<3, 6, 9,
12, 18, and 24 mo. An exploratory subgroup analysis of patients with
0–6 of the IMDC prognostic factors was performed to determine any
differences in OS. Statistical analyses were performed with SAS v.9.2,
defining p < 0.05 (two sided) as statistically significant.
3. Results
3.1. Patient characteristics and outcomes
A total of 2569 of 3245 IMDC mRCC patients (79%) received
a nephrectomy. Patients who had a nephrectomy before the
diagnosis of metastatic disease (ie, those with metachro-
nousmetastases)were excluded (n = 1587). Among remain-
ing patients (n = 1658), 982 underwent a CN; 676 did not.
These were the final numbers for analysis. The median
follow-up of all patients was 39.1 mo (95% confidence
interval [CI], 36.0–41.5). At the time of analysis, 1137
patients (68.6%) had died, and 1416 (85.4%) had experi-
enced disease progression.
All patients received targeted therapy, with most
receiving first-line sunitinib (72%). Table 1 shows the
comparison of baseline characteristics between CN and
non-CN patients. Patients receiving a CN had better IMDC
prognostic profiles: 9% favorable, 63% intermediate, and
28% poor compared with the non-CN profiles, 1% favorable,
45% intermediate, and 54% poor (p < 0.001). Fewer CN
patients had non–clear cell pathology (p = 0.042), bone
metastases (p = 0.001), and liver metastases (p = 0.001),
but CN patients had more sarcomatoid features (<0.001).
3.2. Univariable and multivariable analysis
The median OS for CN patients was 20.6 versus 9.6 mo for
patients not receiving a CN (Fig. 1; p < 0.001). After
adjustment with IMDC risk factors that were different
between the two populations, a clear OS benefit was
Table 1 – Patient characteristics at initiation of targeted therapy by nephrectomy status
Baseline characteristics No CN (n = 676), n/n (%) CN (n = 982), n/n (%) p value
Age, yr* 59.9 (54.6–70.0) 59.3 (52.7–67.4) 0.740
Gender
Male 488/676 (72) 721/982 (73) 0.579
Female 188/676 (28) 261/982 (27)
IMDC prognostic criteria
Favorable 5/482 (1) 65/686 (9) <0.001
Intermediate 215/482 (45) 431/686 (63)
Poor 261/482 (54) 190/686 (28)
KPS <80 233/558 (42) 158/837 (19) <0.001
Diagnosis to targeted therapy <1 yr 639/674 (95) 695/980 (71) <0.001
Serum corrected calcium >ULN 120/601 (20) 76/867 (8.8) <0.001
Hemoglobin <LLN 446/643 (69) 570/907 (63) <0.008
Neutrophils >ULN 166/624 (27) 127/881 (14) <0.001
Platelets >ULN 167/595 (28) 164/803 (20) 0.001
Type of targeted therapy
Sunitinib 533/675 (79) 654/972 (67) <0.001
Sorafenib 58/675 (8.6) 194/972 (20)
Axitinib 3/675 (0.4) 4/972 (0.4)
Bevacizumab 10/675 (1.5) 42/972 (4.0)
Temsirolimus 43/675 (6.4) 35/972 (3.6)
Pazopanib 19/675 (2.8) 27/972 (2.8)
Everolimus 9/675 (1.0) 9/972 (1.0)
Other 2/675 (0.3) 7/972 (0.7)
Non–clear cell pathology 83/533 (16) 113/954 (12) 0.042
Sarcomatoid features 38/442 (8.6) 151/936 (16) <0.001
Bone metastases 305/638 (48) 359/908 (40) 0.001
Liver metastases 153/614 (25) 151/844 (18) 0.001
Brain metastases 64/608 (11) 72/903 (8) 0.089
CN = cytoreductive nephrectomy; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; KPS = Karnofsky performance score;
LLN = lower limit of normal; ULN = upper limit of normal.
* Data are shown as median (interquartile range).
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Fig. 1 – Kaplan-Meier curve depicting the overall survival from the initiation of targeted therapy for 1633 metastatic renal cell carcinoma patients who
did or did not receive a cytoreductive nephrectomy.
CI = confidence interval; CN = cytoreductive nephrectomy; HR = hazard ratio; OS = overall survival.
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p < 0.001). CN was also associated with an increase in PFS:
7.6 mo (95% CI, 6.7–8.1; p < 0.001) versus 4.5 mo (95% CI,
3.9–5.1; p < 0.001). PFS adjustment for prognostic factorscontinued to show a benefit for CN (HR: 0.75; 95% CI, 0.66–
0.85; p < 0.001). Table 2 shows the subgroup analysis of
patients receiving CN compared with those not receiving
CN.
Table 2 – Subgroup analysis of patients receiving and not receiving cytoreductive nephrectomy
Subgroup analysis Median OS, mo Hazard ratio (95% CI) p value
Without CN With CN
Risk
Favorable* 41.0 37.0 – –
Intermediate 13.3 23.0 0.58 (0.47–0.71) <0.001
Poor 6.0 9.5 0.64 (0.52–0.78) <0.001
KPS
>80 12.2 23.4 0.53 (0.45–0.62) <0.001
<80 5.3 8.6 0.70 (0.56–0.88) 0.002
Age at TKI, yr
<75 9.6 20.8 0.52 (0.46–0.59) <0.001
>75 8.6 16.7 0.66 (0.44–0.98) 0.038
No. of metastases
1 15.0 38.6 0.50 (0.38–0.66) <0.001
>1 8.9 17.7 0.55 (0.48–0.63) <0.001
Brain metastases
No 9.5 21.9 0.51 (0.45–0.58) <0.001
Yes 6.9 12.5 0.57 (0.39–0.83) 0.003
Liver metastases
No 10.7 21.5 0.53 (0.46–0.61) <0.001
Yes 6.6 10.6 0.65 (0.51–0.84) 0.001
Bone metastases
No 9.5 24.3 0.48 (0.40–0.56) <0.001
Yes 9.3 14.9 0.65 (0.54–0.77) <0.001
Sarcomatoid
No 10.9 22.3 0.51 (0.44–0.59) <0.001
Yes 5.5 10.2 0.56 (0.36–0.86) 0.009
Non–clear cell
No 10.9 21.4 0.52 (0.45–0.59) <0.001
Yes 8.0 15.3 0.61 (0.43–0.87) 0.006
CI = confidence interval; CN = cytoreductive nephrectomy; KPS = Karnofsky Performance Score; OS = overall survival; TKI = tyrosine kinase inhibitor.
* Numbers too small.
Table 3 – Incremental overall survival benefit from cytoreductive nephrectomy separated by estimated survival times
OS, mo No CN OS, mo CN OS, mo Incremental benefit, mo p value HR (95% CI) adjusted for IMDC criteria
<24 7.1
n = 456
12.3
n = 480
+5.2 <0.0001 0.72 (0.62–0.85)
p < 0.001
n = 676*
<18 6.7
n = 430
10.0
n = 395
+3.3 <0.0001 0.85 (0.72–1.00)
p = 0.05
n = 602*
<12 5.5
n = 366
7.3
n = 290
+2.2 <0.0001 0.97 (0.81–1.17)
p = 0.761
n = 483*
<9 4.5
n = 303
5.5
n = 218
+1.0 0.0027 0.98 (0.79–1.20)
p = 0.811
n = 385*
<6 3.2
n = 230
4.0
n = 151
+0.8 0.0084 1.02 (0.80–1.31)
p = 0.856
n = 280*
<3 2.1
n = 118
2.2
n = 71
+0.1 0.9429 1.03 (0.72–1.46)
p = 0.878
n = 146*
CI = confidence interval; CN = cytoreductive nephrectomy; HR = hazard ratio; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium;
OS = overall survival.
* The n used in the adjusted HR does not match the sum of CN versus no CN patients in each row due to missing data on prognostic factors because a complete
case analysis was used.
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Incremental benefit analysis (Table 3) demonstrated that
the only patient group not to receive an OS benefit from CN
were those estimated to survive <3 mo (2.2 vs 2.1 mo OS:+0.1; p = 0.943). Patients estimated to survive 6 mo
experienced a marginal +0.8 OS increase when a CN was
performed (4.0 vs 3.2moOS; p = 0.008). The longer a patient
was estimated to survive, the greater the OS benefit of CN.
Patients estimated to survive <24 mo had an OS benefit of
Table 4 – Overall survival differences in those with and without cytoreductive nephrectomy by number of International Metastatic Renal
Cell Carcinoma Database Consortium criteria met
No. of IMDC criteria met No CN OS, mo (n) CN OS, mo (n) p value
0 92% of patients (65/71) had CN, insufficient number to compare
1 22.5 (n = 72) 30.4 (n = 178) 0.002
2 10.2 (n = 143) 20.2 (n = 253) <0.001
3 10.0 (n = 113) 15.9 (n = 106) <0.001
4 5.4 (n = 103) 6.0 (n = 67) 0.166
5 3.6 (n = 36) 2.8 (n = 14) 0.504
6 25% of patients (3/12) had CN, insufficient number to compare
Overall, 1168 of 1658 subjects (70%) had complete information about prognostic factors, nephrectomy, and outcomes and were used in this complete case
analysis; the rest were excluded. Shaded rows indicate patient groups that may not benefit from cytoreductive nephrectomy.
CN = cytoreductive nephrectomy; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; OS = overall survival.
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adjusting for prognostic factors, HRs were not significant
for those who lived <3, 6, and 12 mo. Patients who lived
<18 mo (HR: 0.85; 95% CI, 0.72–1.00; p = 0.05) and <24 mo
(HR: 0.72; 95% CI, 0.62–0.85; p < 0.001) were more likely to
derive benefit.
3.4. International Metastatic Renal Cell Carcinoma Database
Consortium criteria for patient selection
Patients with no prognostic factors were not analyzed
because almost all patients (92% [65 of 71]) had CN. At the
other end of the spectrum, those with all six risk factors
representedonly12patients ofwhomonly3 (25%) received a
CN. Those with one, two, and three risk factors seemed to
derive benefit fromCN,whereas thosewith four, five, and six
risk factors did not (Table 4). A test for interaction between
the number of IMDC prognostic factors and nephrectomy
status was statistically significant (p = 0.0005), indicating
that the prognostic factors modify the effect of nephrectomy
on survival.
4. Discussion
The need for CN in the treatment of mRCC during the era of
targeted therapy has been questioned due to the lack of
supporting level 1 evidence. VEGF and mTOR inhibitors
have demonstrated substantial improvements in tumor
shrinkage and survival over previously used immunothera-
pies; thus there is concern over delaying treatment to
perform a CN [2,12–14].
Although nephrectomies are a fairly safe procedure, CNs
carry a higher mortality rate, and they are associated with
higher morbidity and in-hospital complications that may
reduce quality of life during recovery compared with those
without CN [15]. However, CN is used as an inclusion
criterion for some clinical trials or at least included patients
with a vast majority having CN; thus determining if CN is
indeed beneficial will have broad implications as to how
mRCC treatment and research is managed.
To date, this study is the largest analysis demonstrating
that CN provides an OS benefit in patients treated with
targeted therapy while also adjusting for known prognostic
factors. Our findings suggest that a large benefit exists inboth OS and PFS in patients receiving a CN compared with
those without, even after adjusting for imbalances in
prognostic criteria (HR: 0.60; 95% CI, 0.52–0.69; p < 0.001
and HR: 0.75; 95% CI, 0.66–0.85; p < 0.001, respectively).
The results are consistent with our previous analysis of
a smaller cohort of 314 patients from the IMDC that
demonstrated a median OS of 19.8 versus 9.4 mo (p < 0.01)
and an adjusted HR of 0.68 (95% CI, 0.46–0.99; p = 0.04);
however, there were no analyses to elucidate patient
selection criteria [16]. The HR is similar to the EORTC trial
performed in the age of immunotherapy (HR: 0.54; 95% CI,
0.31–0.94) [5].
A large study examining CN and survival in both the era
of immunotherapy and targeted therapy noted an OS of
19 mo for targeted therapy with CN versus only 4 mo for
targeted therapy alone [7]. Because this was performed
with Surveillance Epidemiology and End Results (SEER)
data, prognostic factorswere unavailable and therefore not
adjusted for. The results also showed a steady decrease in
CN utilization, which peaked at 39% in 2004 and has
decreased by 0.6% every year since then [7]. The declining
trend of CN after the introduction of targeted therapy
was observed elsewhere [8]. However, both of these
studies used SEER data that focuses exclusively on the
United States; thus it is difficult to ascertain if this is a
global trend.
Careful patient selection is critical in determining if a
patient will benefit from a CN because those with poor
survival outcome or who are likely to progress rapidly may
receiveminimal benefit. In our incremental benefit analysis,
CN provided an increase in OS for patients surviving<6mo;
however, when adjusted for prognostic factors, a significant
HRwas not observed until the<18-mo group. Thus patients
expected to survive <12 mo may receive marginal benefit
from a CN. Patients with four, five, and six IMDC risk factors
did not appear to derive benefit.
Strengths of our analysis include the large multicenter
series of patients that focuses on patients treated with
targeted therapies [17]. Unlike clinical trials, the IMDC does
not have inclusion criteria, strengthening its use as a
population-based method of analysis. To our knowledge,
this study is novel in examining the incremental benefits of
CN and using the IMDC prognostic model factors to aid in
patient selection.
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tive and patients may be prone to selection bias, although
the use of consecutive patient series from registry and
pharmacy data attempted tomitigate that. Our study is also
limited in our ability to adjust for prognostic factors that are
unknown or not collected because it is not possible to
control for all factors, and we were unable to account for
perioperative mortality or surgery-related morbidity. Miss-
ing data were handled using a complete case analysis; thus
any patient with a missing prognostic factor would be
excluded from the adjusted analyses to provide the most
conservative estimate. To ensure there was not a systematic
bias associated with the patients with missing data,
outcomes were compared between these patients and
those without missing data, and no differences were noted
in OS (data not shown). Finally, some patients may have
received their CN before the initiation of targeted therapy
that may bias the OS estimate against those with CN;
however, this makes the analysis more robust because it
may underestimate the OS benefit.
The Clinical Trial to Assess the Importance of Nephrec-
tomy (CARMENA; NCT00930033) will study patients with
good performance status (Eastern Cooperative Oncology
Group 0 or 1) and randomly assign them to nephrectomy
followed by the targeted therapy sunitinib or sunitinib
alone. The Immediate Surgery or Surgery After Sunitinib
Malate in Treating Patients with Metastatic Kidney Cancer
(SURTIME; NCT01099423) clinical trial investigates the
benefit of treating mRCC patients with sunitinib before CN
as well as after, compared with sunitinib only after CN.
However, these trials are not anticipated to report for some
time, so these retrospective data may guide us until then.
Combined, the results of these trials will have a more
definitive answer for the role of CN inmRCC patients treated
with targeted therapy.
5. Conclusions
Our findings demonstrate that CN may provide an OS
benefit in mRCC patients treated with targeted therapy.
Patientswith limited expected survival or thosewith four or
more IMDC prognostic factors may not receive a substantial
benefit compared with those expected to survive longer.
Stringent patient selection remains vital as we await results
from the randomized controlled trials.
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